title: An exceptional overall survival using bevacizumab beyond progression in a patient with non-small cell lung cancer.
abstract: Non-small cell lung cancer (NSCLC) is the most common malignancy and the leading cause of cancer death worldwide. In this report, we describe a patient with NSCLC who was treated with continuation of Bevacizumab (Bev) beyond progression to first-line Bev-based chemotherapy. The prolonged treatment with Bev by continuing the inhibition of VEGF beyond first-progression has a strong rationale. Nevertheless, few data exist regarding the efficacy and safety of Bev beyond first line of chemotherapy progression in NSCLC patients. Further studies including a large number of patients are needed, in order to select patients who could benefit from this approach.
authors.affiliation: a Medical Oncology Unit; University of Siena ; Siena , Italy.
authors.forename: Giandomenico
authors.initials: G
authors.lastname: Roviello
authors.affiliation: b Medical Oncology Unit; Policlinico Umberto I Hospital; University of Rome ; Roma , Italy.
authors.forename: Edoardo
authors.initials: E
authors.lastname: Francini
authors.affiliation: a Medical Oncology Unit; University of Siena ; Siena , Italy.
authors.forename: Armando
authors.initials: A
authors.lastname: Perrella
authors.affiliation: a Medical Oncology Unit; University of Siena ; Siena , Italy.
authors.forename: Letizia
authors.initials: L
authors.lastname: Laera
authors.affiliation: c Department of Medical ; Surgical and Neurosciences; Diagnostic Imaging; University of Siena ; Siena , Italy.
authors.forename: Maria Antonietta
authors.initials: MA
authors.lastname: Mazzei
authors.affiliation: c Department of Medical ; Surgical and Neurosciences; Diagnostic Imaging; University of Siena ; Siena , Italy.
authors.forename: Susanna
authors.initials: S
authors.lastname: Guerrini
authors.affiliation: a Medical Oncology Unit; University of Siena ; Siena , Italy.
authors.forename: Roberto
authors.initials: R
authors.lastname: Petrioli
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab / Q000008:administration & dosage / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology*; D018450:Disease Progression; D017809:Fatal Outcome; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D013902:Radiography, Thoracic; D019233:Retreatment; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D000068258:Bevacizumab
keywords: bevacizumab; chemotherapy; non-small cell lung cancer